{
    "clinical_study": {
        "@rank": "68754", 
        "arm_group": [
            {
                "arm_group_label": "Bimatoprost 0.01%", 
                "arm_group_type": "Experimental", 
                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae 0.01%) administered each evening in both eyes for 6 weeks."
            }, 
            {
                "arm_group_label": "Bimatoprost 0.03%", 
                "arm_group_type": "Active Comparator", 
                "description": "Bimatoprost 0.03% (LUMIGAN\u00ae 0.03%) administered each evening in both eyes for 6 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or\n      ocular hypertension (OHT)."
        }, 
        "brief_title": "A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of glaucoma or ocular hypertension\n\n        Exclusion Criteria:\n\n          -  Active ocular disease other than glaucoma or ocular hypertension\n\n          -  Require chronic use of ocular medications other than the study medication during the\n             study (intermittent use of artificial tear solution will be permitted)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "440", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01830140", 
            "org_study_id": "192024-081"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bimatoprost 0.01%", 
                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae 0.01%) administered each evening in both eyes for 6 weeks.", 
                "intervention_name": "Bimatoprost 0.01%", 
                "intervention_type": "Drug", 
                "other_name": "LUMIGAN\u00ae 0.01%"
            }, 
            {
                "arm_group_label": "Bimatoprost 0.03%", 
                "description": "Bimatoprost 0.03% (LUMIGAN\u00ae 0.03%) administered each evening in both eyes for 6 weeks.", 
                "intervention_name": "Bimatoprost 0.03%", 
                "intervention_type": "Drug", 
                "other_name": "LUMIGAN\u00ae 0.03%"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bimatoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 13, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Artesia", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "El Paso", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Patients with an Increase in Macroscopic Conjunctival Hyperemia", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 6 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01830140"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}